Financial Performance - For the fiscal year ending March 31, 2022, the total revenue was HKD 92,873 thousand, a decrease of 9.4% from HKD 102,041 thousand in the previous year[11]. - The company reported a net loss of HKD 31,260 thousand for the year, compared to a net loss of HKD 2,346 thousand in the previous year, indicating a significant decline in performance[4]. - The gross profit for the year was HKD 13,754 thousand, down from HKD 28,322 thousand in the previous year, reflecting a decrease of 51.4%[4]. - Revenue for the health products and services segment reached HKD 98,953,000, representing an increase from HKD 92,118,000 in the previous year, a growth of approximately 7.9%[19]. - The segment profit for health products and services was HKD 7,741,000, up from HKD 3,709,000, indicating a significant improvement in profitability[20]. - Total revenue for the company was HKD 102,041,000, compared to HKD 92,873,000 in the prior year, reflecting an overall growth of about 9.5%[20]. - The company reported a pre-tax profit of HKD 641,000 for the year, a turnaround from a pre-tax loss of HKD 30,629,000 in the previous year[20]. - The basic loss per share was HKD 0.0242, compared to HKD 0.0038 in the previous year, indicating a deterioration in earnings per share[31]. - The company reported a loss of approximately HKD 31,260,000 for the year, an increase of about HKD 28,910,000 compared to a loss of HKD 2,350,000 the previous year[49]. Assets and Liabilities - The company's total assets decreased to HKD 197,048 thousand from HKD 258,775 thousand, a decline of 23.8% year-over-year[6]. - The company's cash and cash equivalents increased to HKD 37,402 thousand from HKD 8,574 thousand, showing a significant improvement in liquidity[6]. - The company’s equity attributable to owners decreased to HKD 265,749 thousand from HKD 290,582 thousand, a reduction of 8.5%[6]. - Non-current assets in China increased to HKD 105,473,000 from HKD 54,341,000, showing a substantial growth of approximately 94.3%[23]. - The company’s total receivables increased to HKD 159,636,000 from HKD 173,378,000, reflecting a decrease in receivables[33]. - The provision for trade receivables at the end of the reporting period was HKD 139,000, up from HKD 133,000, indicating a slight increase in credit risk[35]. - The aging analysis of trade receivables showed that HKD 20,902,000 was overdue by more than 181 days as of March 31, 2022, compared to HKD 2,708,000 the previous year[38]. - The group's net current assets as of March 31, 2022, were approximately HKD 163,830,000, including cash and cash equivalents of about HKD 37,400,000, compared to HKD 228,450,000 and HKD 8,570,000 respectively as of March 31, 2021[63]. - The group had no debt as of March 31, 2022, resulting in a capital-to-debt ratio of zero, consistent with the previous year[63]. Operational Highlights - The company is primarily engaged in health products and services, as well as lending activities, with all revenue recognized in China[13]. - The health products and services business is expected to have broad prospects, driven by improving living standards and health awareness in China and globally[59]. - The group plans to use the proceeds from the sale of a 15% stake in Beijing Lianhe Zhongcheng Medical Technology Co., Ltd., valued at RMB 30,000,000, to enrich its general working capital and existing business[66]. - The company plans to expand and diversify its offerings in genetic testing and health data analysis products, as well as stem cell and innovative medical technology products[53]. - The group aims to continue identifying suitable new business opportunities and investment projects to maximize returns for shareholders[60]. - The group has reduced its workforce to 15 full-time employees as of March 31, 2022, down from 19 in the previous year, due to a focus on distributor sales marketing strategies[73]. Audit and Compliance - The company has not completed the audit procedures for the fiscal year, which may affect the publication of the audited financial results[2]. - The audit process for the fiscal year ending March 31, 2022, was adversely affected due to COVID-19 restrictions in mainland China, particularly in Beijing, where the company's headquarters are located[84]. - The unaudited full-year results for the fiscal year ending March 31, 2022, have not yet been agreed upon with the company's auditor, Zhonghui Anda CPA Limited[84]. - The company plans to announce the audited results for the fiscal year ending March 31, 2022, once the audit process is completed[85]. - The company will disclose any significant differences between the audited results and the unaudited results once they are available[85]. - The company will hold an annual general meeting, with the proposed date to be announced later[85]. - Arrangements for shareholder attendance and voting at the annual general meeting will be communicated separately[85]. Dividends and Contingent Liabilities - The company did not recommend any dividends for the fiscal year ending March 31, 2022, consistent with the previous year[29]. - The group has not proposed a final dividend for the year ending March 31, 2022, consistent with the previous year[61]. - The group has no significant contingent liabilities as of March 31, 2022[71]. - The group has not pledged any assets as collateral as of March 31, 2022[70].
莲和医疗(00928) - 2022 Q4 - 年度财报